trending Market Intelligence /marketintelligence/en/news-insights/trending/hrMKAvXu5UFiLK2VtOD5zw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Moody's upgrades Horizon Pharma's corporate family rating

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Moody's upgrades Horizon Pharma's corporate family rating

Moody's on March 20 upgraded the corporate family rating of Dublin-based Horizon Pharma PLC's U.S. unit Horizon Pharma USA Inc. to Ba3 from B2.

The outlook on the ratings is stable.

Moody's said the upgrade reflects significant debt repayments with proceeds from a public equity offering.

The rating agency also raised the probability of default rating to Ba3-PD from B2-PD, the senior secured rating to Ba1 from Ba2 and the senior unsecured rating to B1 from B3. Moody's affirmed the speculative grade liquidity rating at SGL-1.

Moody's said the Ba3 corporate family rating reflects the company's modest size compared to other companies in the global pharmaceutical industry with annual revenue of about $1.2 billion.

The upgrade in the corporate family rating considers the good growth outlook for Horizon's key drugs like Krystexxa, Ravicti and Procysbi, and also takes into account the agency's expectation for the regulatory approval of teprotumumab in thyroid eye disease, which has strong sales potential based on unmet medical need.

Moody's said the stable outlook reflects its expectation for solid growth in Horizon's orphan disease and rheumatology products and gross debt/EBITDA sustained below 4.5x.